Early intensive insulin therapy attenuates the p38 pathway in the renal cortex and indices of nephropathy in diabetic rats

Endocrine Journal

Volumn 59, Issue 1, 2012, Pages 81-90

  Fang, Donghong ^a   Guan, Hongyu ^a   Liu, Juan ^a   Wei, Guohong ^a   Ke, Weijian ^a   Yao, Bin ^a   Xiao, Haipeng ^a   Li, Yanbing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Early intensive insulin treatment; Metabolic memory; P38 mitogen activated protein kinase (MAPK)

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ISOPHANE INSULIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; EXTRACELLULAR MATRIX; GLYCEMIC CONTROL; INSULIN TREATMENT; KIDNEY CORTEX; KIDNEY HYPERTROPHY; LIPID DIET; MALE; MESANGIUM; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; GLOMERULAR MESANGIUM; HUMANS; HYPERTROPHY; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, REGULAR, HUMAN; KIDNEY CORTEX; KIDNEY GLOMERULUS; MALE; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIME FACTORS;

EID: 84863063784     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ11-0057     Document Type: Article

References (21)

1. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J (2004) Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 27: 2597-2602.
2. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371: 1753-1760.
3. Kang SW, Adler SG, Lapage J, Natarajan R (2001) p38 MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. Kidney Int 60: 543-552.
4. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R (1997) Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 46: 847-853.
5. Komers R, Lindsley JN, Oyama TT, Cohen DM, Anderson S (2007) Renal p38 MAP kinase activity in experimental diabetes. Lab Invest 87: 548-558.
6. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52: 313-320.
7. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H (2003) Intercellular adhesion molecule-1-defcient mice are resistant against renal injury after induction of diabetes. Diabetes 52: 2586-2593.
8. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K (2003) Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46: 843-851.
9. Zhang J, Bui T N, Xiang J, Lin A (2006) Cyclic AMP inhibits p38 activation via CREB-induced dynein light chain. Mol Cell Biol 26: 1223-1234.
10. Xu ZG, Kim KS, Park HC, Choi KH, Lee HY, Han DS, Kang SW (2003) High glucose activates the p38 MAPK pathway in cultured human peritoneal mesothe-lial cells. Kidney Int 63: 958-968.
11. Nystrom FH, Quon MJ (1999) Insulin signalling: metabolic pathways and mechanisms for specifcity. Cell Signal 11: 563-574.
12. Figarola J L, Loera S, Weng Y, Shanmugam N, Natarajan R, Rahbar S (2008) LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia 51: 882-891.
13. Wei XF, Zhou QG, Hou FF, Liu BY, Liang M (2009) Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase. Am J Physiol Renal Physiol 296: F427-437.
14. Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, Forino M, Facchin S, Bordin L, Weigert C, Nerlich A, Schleicher ED (2000) Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11: 2324-2336.
15. Potenza MA, Addabbo F, Montagnani M (2009) Vascular actions of insulin with implications for endothelial dysfunction. Am J Physiol Endocrinol Metab 297: E568-577.
16. Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, Pons DA, Owen RJ, Satchell SC, Miles MJ, Caunt CJ, McArdle C A, Pavenstadt H, Tavare J M, Herzenberg A M, Kahn C R, Mathieson P W, Quaggin S E, Saleem MA, Coward RJ (2010) Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 12: 329-340.
17. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986.
18. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M (2000) Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 48: 201-210.
19. Kowluru R A, Abbas S N, Odenbach S (2004) Reversal of hyperglycemia and diabetic nephropathy: effect of reinstitution of good metabolic control on oxida-tive stress in the kidney of diabetic rats. J Diabetes Complications 18: 282-288.
20. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287: 2563-2569.
21. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan B E, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572.